Source: Clinics. Conference titles: LAGID Meeting of the Autoimmunity in Primary Immunodeficiencies. Unidade: ICB
Assunto: IMUNOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, E. B. et al. BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase, activates of human NADPH oxidase system from THP-1 cells: a potential adjuvant for infection control of immunodeficient patients. Clinics. São Paulo: Instituto de Ciências Biomédicas, Universidade de São Paulo. . Acesso em: 22 ago. 2024. , 2007APA
Oliveira, E. B., Thomazzi, S. M., Rehder, J., Antunes, E., & Condino Neto, A. (2007). BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase, activates of human NADPH oxidase system from THP-1 cells: a potential adjuvant for infection control of immunodeficient patients. Clinics. São Paulo: Instituto de Ciências Biomédicas, Universidade de São Paulo.NLM
Oliveira EB, Thomazzi SM, Rehder J, Antunes E, Condino Neto A. BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase, activates of human NADPH oxidase system from THP-1 cells: a potential adjuvant for infection control of immunodeficient patients. Clinics. 2007 ; 62[citado 2024 ago. 22 ]Vancouver
Oliveira EB, Thomazzi SM, Rehder J, Antunes E, Condino Neto A. BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase, activates of human NADPH oxidase system from THP-1 cells: a potential adjuvant for infection control of immunodeficient patients. Clinics. 2007 ; 62[citado 2024 ago. 22 ]
